BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med 2018;10:eaar3483. [PMID: 30158150 DOI: 10.1126/scitranslmed.aar3483] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 28.3] [Reference Citation Analysis]
Number Citing Articles
1 Ding H, Kiguchi N, Mabry KM, Kishioka S, Ko M. Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109328] [Reference Citation Analysis]
2 Wtorek K, Ghidini A, Gentilucci L, Adamska-Bartłomiejczyk A, Piekielna-Ciesielska J, Ruzza C, Sturaro C, Calò G, Pieretti S, Kluczyk A, McDonald J, Lambert DG, Janecka A. Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors. Int J Mol Sci 2022;23:12700. [PMID: 36293553 DOI: 10.3390/ijms232012700] [Reference Citation Analysis]
3 Zhang J, Song C, Dai J, Li L, Yang X, Chen Z. Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu‐opioid receptor. MedComm 2022;3. [DOI: 10.1002/mco2.148] [Reference Citation Analysis]
4 Gerak LR, Maguire DR, Cami-Kobeci G, Olson KM, Traynor JR, Husbands SM, France CP, Acevedo L, Belli B, Flynn P. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects. Behav Pharmacol 2022;33:377-94. [PMID: 35947066 DOI: 10.1097/FBP.0000000000000684] [Reference Citation Analysis]
5 Coluzzi F, Rullo L, Scerpa MS, Losapio LM, Rocco M, Billeci D, Candeletti S, Romualdi P. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. CNS Drugs 2022. [PMID: 35616826 DOI: 10.1007/s40263-022-00924-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Dasgupta P, Mann A, Polgar WE, Reinscheid RK, Zaveri NT, Schulz S. Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics. Sci Rep 2022;12:7154. [PMID: 35504962 DOI: 10.1038/s41598-022-11189-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cippitelli A, Martinez M, Zribi G, Cami-kobeci G, Husbands SM, Toll L. PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Juřica J. Dual opioid analgesia. Prakticke lekarenstvi 2022;18:48-52. [DOI: 10.36290/lek.2022.007] [Reference Citation Analysis]
9 Cox BM, Toll L. Contributions of the International Narcotics Research Conference to Opioid Research Over the Past 50 years. Adv Drug Alcohol Res 2022;2. [DOI: 10.3389/adar.2022.10115] [Reference Citation Analysis]
10 Kiguchi N, Ding H, Park SH, Mabry KM, Kishioka S, Shiozawa Y, Alfonso Romero-Sandoval E, Peters CM, Ko MC. Functional roles of neuromedin B and gastrin-releasing peptide in regulating itch and pain in the spinal cord of non-human primates. Biochem Pharmacol 2022;198:114972. [PMID: 35189108 DOI: 10.1016/j.bcp.2022.114972] [Reference Citation Analysis]
11 Somogyi AA, Musolino ST, Barratt DT. New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesth Intensive Care 2022;:310057X211063891. [PMID: 35112584 DOI: 10.1177/0310057X211063891] [Reference Citation Analysis]
12 Bird MF, Mcdonald J, Horley B, O’doherty JP, Fraser B, Gibson CL, Guerrini R, Caló G, Lambert DG. MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands. PLoS ONE 2022;17:e0260880. [DOI: 10.1371/journal.pone.0260880] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 El Daibani A, Che T. Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain. Molecules 2022;27:595. [PMID: 35163856 DOI: 10.3390/molecules27030595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kiguchi N, Ko M. Potential therapeutic targets for the treatment of opioid abuse and pain. Behavioral Pharmacology of Drug Abuse: Current Status 2022. [DOI: 10.1016/bs.apha.2021.09.002] [Reference Citation Analysis]
15 Griffith JI, Kim M, Bruce DJ, Peterson CD, Kitto KF, Mohammad AS, Rathi S, Fairbanks CA, Wilcox GL, Elmquist WF. Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity. J Pharmacol Exp Ther 2022;380:34-46. [PMID: 34663676 DOI: 10.1124/jpet.121.000821] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Varshneya NB, Hassanien SH, Holt MC, Stevens DL, Layle NK, Bassman JR, Iula DM, Beardsley PM. Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated. Biochem Pharmacol 2021;:114805. [PMID: 34673011 DOI: 10.1016/j.bcp.2021.114805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Noble F, Marie N. Biased Opioid Ligands: Revolution or Evolution? Front Pain Res 2021;2. [DOI: 10.3389/fpain.2021.722820] [Reference Citation Analysis]
18 Bossert JM, Townsend EA, Altidor LK, Fredriksson I, Shekara A, Husbands S, Sulima A, Rice KC, Banks ML, Shaham Y. Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance. Br J Pharmacol 2021. [PMID: 34505281 DOI: 10.1111/bph.15679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Dahan A, Olofsen E. Does Divergence Exist between Animal and Human Data on the Effect of Cebranopadol? Anesthesiology 2021;135:382-3. [PMID: 34329373 DOI: 10.1097/ALN.0000000000003885] [Reference Citation Analysis]
20 Chakraborty S, Uprety R, Daibani AE, Rouzic VL, Hunkele A, Appourchaux K, Eans SO, Nuthikattu N, Jilakara R, Thammavong L, Pasternak GW, Pan YX, McLaughlin JP, Che T, Majumdar S. Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom. ACS Chem Neurosci 2021;12:2661-78. [PMID: 34213886 DOI: 10.1021/acschemneuro.1c00149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
21 Hill R, Canals M. Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology. Pharmacol Ther 2021;:107961. [PMID: 34256067 DOI: 10.1016/j.pharmthera.2021.107961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Kiguchi N, Ding H, Kishioka S, Ko MC. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics. Curr Top Med Chem 2020;20:2878-88. [PMID: 32384033 DOI: 10.2174/1568026620666200508082615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
23 Shamakina IY, Shagiakhmetov FS, Anokhin PK, Kohan VS, Davidova TV. The Role of Nociceptin in Opioid Regulation of Brain Functions. Biochem Moscow Suppl Ser B 2021;15:171-183. [DOI: 10.1134/s1990750821030094] [Reference Citation Analysis]
24 Wang Z, Jiang C, He Q, Matsuda M, Han Q, Wang K, Bang S, Ding H, Ko MC, Ji RR. Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Sci Transl Med 2020;12:eaaw6471. [PMID: 32075945 DOI: 10.1126/scitranslmed.aaw6471] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 32.0] [Reference Citation Analysis]
25 Ding H, Trapella C, Kiguchi N, Hsu FC, Caló G, Ko MC. Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates. Anesthesiology 2021. [PMID: 34237134 DOI: 10.1097/ALN.0000000000003848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
26 Scholz O, Otter S, Welters A, Wörmeyer L, Dolenšek J, Klemen MS, Pohorec V, Eberhard D, Mrugala J, Hamacher A, Koch A, Sanz M, Hoffmann T, Hogeback J, Herebian D, Klöcker N, Piechot A, Mayatepek E, Meissner T, Stožer A, Lammert E. Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets. Cell Chem Biol 2021:S2451-9456(21)00256-7. [PMID: 34118188 DOI: 10.1016/j.chembiol.2021.05.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Toll L, Cippitelli A, Ozawa A. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies. CNS Drugs 2021;35:591-607. [PMID: 34057709 DOI: 10.1007/s40263-021-00821-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Dumitrascuta M, Bermudez M, Trovato O, De Neve J, Ballet S, Wolber G, Spetea M. Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking. Molecules 2021;26:3267. [PMID: 34071603 DOI: 10.3390/molecules26113267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
29 Deng J, Hou W, Dong X, Hajagos J, Saltz M, Saltz J, Wang F. A Large-Scale Observational Study on the Temporal Trends and Risk Factors of Opioid Overdose: Real-World Evidence for Better Opioids. Drugs Real World Outcomes 2021;8:393-406. [PMID: 34037960 DOI: 10.1007/s40801-021-00253-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Pacifico S, Albanese V, Illuminati D, Marzola E, Fabbri M, Ferrari F, Holanda VAD, Sturaro C, Malfacini D, Ruzza C, Trapella C, Preti D, Lo Cascio E, Arcovito A, Della Longa S, Marangoni M, Fattori D, Nassini R, Calò G, Guerrini R. Novel Mixed NOP/Opioid Receptor Peptide Agonists. J Med Chem 2021;64:6656-69. [PMID: 33998786 DOI: 10.1021/acs.jmedchem.0c02062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lu JJ, Polgar WE, Mann A, Dasgupta P, Schulz S, Zaveri NT. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor. Mol Pharmacol 2021;100:7-18. [PMID: 33958480 DOI: 10.1124/molpharm.120.000076] [Reference Citation Analysis]
32 De Neve J, Barlow TMA, Tourwé D, Bihel F, Simonin F, Ballet S. Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. RSC Med Chem 2021;12:828-70. [PMID: 34223156 DOI: 10.1039/d1md00041a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
33 Ding H, Ko MC. Translational value of non-human primates in opioid research. Exp Neurol 2021;338:113602. [PMID: 33453211 DOI: 10.1016/j.expneurol.2021.113602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
34 Reinscheid RK, Schulz S. Opioid Systems. Encyclopedia of Molecular Pharmacology 2021. [DOI: 10.1007/978-3-030-57401-7_108] [Reference Citation Analysis]
35 Ko MC, Husbands SM. Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates. Handb Exp Pharmacol 2020. [PMID: 33274403 DOI: 10.1007/164_2020_419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
36 Zhang M, Xu B, Li N, Liu H, Shi X, Zhang Q, Shi Y, Xu K, Xiao J, Chen D, Zhu H, Sun Y, Zhang T, Zhang R, Fang Q. Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception. J Med Chem 2020;63:15709-25. [PMID: 33271020 DOI: 10.1021/acs.jmedchem.0c01367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Starnowska-Sokół J, Przewłocka B. Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges. Molecules 2020;25:E5520. [PMID: 33255641 DOI: 10.3390/molecules25235520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 Faouzi A, Uprety R, Gomes I, Massaly N, Keresztes AI, Le Rouzic V, Gupta A, Zhang T, Yoon HJ, Ansonoff M, Allaoa A, Pan YX, Pintar J, Morón JA, Streicher JM, Devi LA, Majumdar S. Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template. J Med Chem 2020;63:13618-37. [PMID: 33170687 DOI: 10.1021/acs.jmedchem.0c00901] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
39 Gibula-Tarlowska E, Kotlinska JH. Crosstalk between Opioid and Anti-Opioid Systems: An Overview and Its Possible Therapeutic Significance. Biomolecules 2020;10:E1376. [PMID: 32998249 DOI: 10.3390/biom10101376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
40 Busserolles J, Ben Soussia I, Pouchol L, Marie N, Meleine M, Devilliers M, Judon C, Schopp J, Clémenceau L, Poupon L, Chapuy E, Richard S, Noble F, Lesage F, Ducki S, Eschalier A, Lolignier S. TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects. Br J Pharmacol 2020;177:4782-95. [PMID: 32851651 DOI: 10.1111/bph.15243] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
41 Faouzi A, Varga BR, Majumdar S. Biased Opioid Ligands. Molecules 2020;25:4257. [DOI: 10.3390/molecules25184257] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 20.5] [Reference Citation Analysis]
42 Ding H, Kiguchi N, Perrey DA, Nguyen T, Czoty PW, Hsu FC, Zhang Y, Ko MC. Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. Br J Anaesth 2020;125:596-604. [PMID: 32819621 DOI: 10.1016/j.bja.2020.06.057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
43 Bodnar RJ. Endogenous Opiates and Behavior: 2018. Peptides 2020;132:170348. [PMID: 32574695 DOI: 10.1016/j.peptides.2020.170348] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
44 Weiss N, Zamponi GW. Opioid Receptor Regulation of Neuronal Voltage-Gated Calcium Channels. Cell Mol Neurobiol 2021;41:839-47. [PMID: 32514826 DOI: 10.1007/s10571-020-00894-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Stein C. Opioid analgesia: recent developments. Current Opinion in Supportive & Palliative Care 2020;14:112-7. [DOI: 10.1097/spc.0000000000000495] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
46 Delery EC, Edwards S. Neuropeptide and cytokine regulation of pain in the context of substance use disorders. Neuropharmacology 2020;174:108153. [PMID: 32470337 DOI: 10.1016/j.neuropharm.2020.108153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Rudolf GD. Buprenorphine in the Treatment of Chronic Pain. Physical Medicine and Rehabilitation Clinics of North America 2020;31:195-204. [DOI: 10.1016/j.pmr.2020.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
48 Kiguchi N, Ding H, Ko MC. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. J Neurosci Res 2020. [PMID: 32255240 DOI: 10.1002/jnr.24624] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
49 Zhao L, Luo K, Wang Z, Wang Y, Zhang X, Yang D, Ma M, Zhou J, Cui J, Wang J, Han CZ, Liu X, Wang R. Design, synthesis, and biological activity of new endomorphin analogs with multi-site modifications. Bioorg Med Chem 2020;28:115438. [PMID: 32199689 DOI: 10.1016/j.bmc.2020.115438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Busserolles J, Lolignier S, Kerckhove N, Bertin C, Authier N, Eschalier A. Replacement of current opioid drugs focusing on MOR-related strategies. Pharmacol Ther 2020;210:107519. [PMID: 32165137 DOI: 10.1016/j.pharmthera.2020.107519] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
51 Targowska-Duda KM, Ozawa A, Bertels Z, Cippitelli A, Marcus JL, Mielke-Maday HK, Zribi G, Rainey AN, Kieffer BL, Pradhan AA, Toll L. NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice. Neuropharmacology 2020;170:108029. [PMID: 32278976 DOI: 10.1016/j.neuropharm.2020.108029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
52 Kiguchi N, Uta D, Ding H, Uchida H, Saika F, Matsuzaki S, Fukazawa Y, Abe M, Sakimura K, Ko MC, Kishioka S. GRP receptor and AMPA receptor cooperatively regulate itch-responsive neurons in the spinal dorsal horn. Neuropharmacology 2020;170:108025. [PMID: 32142790 DOI: 10.1016/j.neuropharm.2020.108025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
53 Reinscheid RK, Schulz S. Opioid Systems. Encyclopedia of Molecular Pharmacology 2020. [DOI: 10.1007/978-3-030-21573-6_108-1] [Reference Citation Analysis]
54 Xu B, Zhang M, Shi X, Zhang R, Chen D, Chen Y, Wang Z, Qiu Y, Zhang T, Xu K, Zhang X, Liedtke W, Wang R, Fang Q. The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors. Br J Pharmacol 2020;177:93-109. [PMID: 31444977 DOI: 10.1111/bph.14848] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
55 Kreek MJ, Reed B, Butelman ER. Current status of opioid addiction treatment and related preclinical research. Sci Adv 2019;5:eaax9140. [PMID: 31616793 DOI: 10.1126/sciadv.aax9140] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
56 Pacifico S, Albanese V, Illuminati D, Fantinati A, Marzola E, Ferrari F, Neto JA, Sturaro C, Ruzza C, Calò G, Preti D, Guerrini R. Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. Bioconjugate Chem 2019;30:2444-51. [DOI: 10.1021/acs.bioconjchem.9b00519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Preti D, Caló G, Guerrini R. NOP-Targeted Peptide Ligands. Handb Exp Pharmacol 2019;254:17-36. [PMID: 30689091 DOI: 10.1007/164_2018_198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
58 Ciccocioppo R, Borruto AM, Domi A, Teshima K, Cannella N, Weiss F. NOP-Related Mechanisms in Substance Use Disorders. Handb Exp Pharmacol 2019;254:187-212. [PMID: 30968214 DOI: 10.1007/164_2019_209] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
59 Kiguchi N, Ko MC. Effects of NOP-Related Ligands in Nonhuman Primates. Handb Exp Pharmacol 2019;254:323-43. [PMID: 30879202 DOI: 10.1007/164_2019_211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
60 Tzschentke TM, Linz K, Koch T, Christoph T. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors. Handb Exp Pharmacol 2019;254:367-98. [PMID: 30927089 DOI: 10.1007/164_2019_206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
61 Chao PK, Chang HF, Chang WT, Yeh TK, Ou LC, Chuang JY, Tsu-An Hsu J, Tao PL, Loh HH, Shih C, Ueng SH, Yeh SH. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine. Neuropharmacology 2020;166:107678. [PMID: 31278929 DOI: 10.1016/j.neuropharm.2019.107678] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
62 Azzam AA, Mcdonald J, Lambert DG. Hot topics in opioid pharmacology: mixed and biased opioids. British Journal of Anaesthesia 2019;122:e136-45. [DOI: 10.1016/j.bja.2019.03.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 25.3] [Reference Citation Analysis]
63 Lambert DG. Mixed mu-nociceptin/orphanin FQ opioid receptor agonists and the search for the analgesic holy grail. British Journal of Anaesthesia 2019;122:e95-7. [DOI: 10.1016/j.bja.2019.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Toll L, Ozawa A, Cippitelli A. NOP-Related Mechanisms in Pain and Analgesia. In: Ko M, Caló G, editors. The Nociceptin/Orphanin FQ Peptide Receptor. Cham: Springer International Publishing; 2019. pp. 165-86. [DOI: 10.1007/164_2019_214] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
65 Sisignano M, Parnham MJ, Geisslinger G. Novel Approaches to Persistent Pain Therapy. Trends Pharmacol Sci 2019;40:367-77. [PMID: 31078322 DOI: 10.1016/j.tips.2019.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Flynn SM, Epperly PM, Davenport AT, Cami-Kobeci G, Husbands SM, Ko MC, Czoty PW. Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys. Neuropsychopharmacology 2019;44:1476-84. [PMID: 30970376 DOI: 10.1038/s41386-019-0390-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
67 Nastase AF, Anand JP, Bender AM, Montgomery D, Griggs NW, Fernandez TJ, Jutkiewicz EM, Traynor JR, Mosberg HI. Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design. J Med Chem 2019;62:4193-203. [PMID: 30916966 DOI: 10.1021/acs.jmedchem.9b00378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
68 Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal 2019;12:eaau8072. [PMID: 30914485 DOI: 10.1126/scisignal.aau8072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
69 Cunningham CW, Elballa WM, Vold SU. Bifunctional opioid receptor ligands as novel analgesics. Neuropharmacology 2019;151:195-207. [PMID: 30858102 DOI: 10.1016/j.neuropharm.2019.03.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
70 Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Br J Anaesth 2019;122:e146-56. [PMID: 30916003 DOI: 10.1016/j.bja.2018.10.065] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
71 Noble F, Marie N. Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine. Front Psychiatry 2018;9:742. [PMID: 30713510 DOI: 10.3389/fpsyt.2018.00742] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
72 Zaveri NT, Meyer ME. NOP-Targeted Nonpeptide Ligands. Handb Exp Pharmacol 2019;254:37-67. [PMID: 31119463 DOI: 10.1007/164_2019_213] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
73 Pasternak GW, Childers SR, Pan YX. Emerging Insights into Mu Opioid Pharmacology. Handb Exp Pharmacol 2020;258:89-125. [PMID: 31598835 DOI: 10.1007/164_2019_270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
74 Parker KE, Bruchas MR. Pain Wars: A New Hope. Neuron 2018;100:1280-2. [PMID: 30571940 DOI: 10.1016/j.neuron.2018.11.045] [Reference Citation Analysis]
75 Rasmussen K, White DA, Acri JB. NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology 2019;44:657-9. [PMID: 30538289 DOI: 10.1038/s41386-018-0292-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
76 Machelska H, Celik MÖ. Advances in Achieving Opioid Analgesia Without Side Effects. Front Pharmacol 2018;9:1388. [PMID: 30555325 DOI: 10.3389/fphar.2018.01388] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 19.8] [Reference Citation Analysis]
77 Majeed MH, Sherazi SAA, Bacon D, Bajwa ZH. Pharmacological Treatment of Pain in Osteoarthritis: A Descriptive Review. Curr Rheumatol Rep 2018;20. [DOI: 10.1007/s11926-018-0794-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
78 Massaly N, Morón JA. Pain And Opioid Systems, Implications In The Opioid Epidemic. Curr Opin Behav Sci 2019;26:69-74. [PMID: 30984806 DOI: 10.1016/j.cobeha.2018.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]